Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
HIV Eradication: One Step Closer
Life Expectancy With HIV Increases Dramatically
Mouth Full of Problems: A Crisis in HIV Dental Care
New Technology Finds Meds That Might Flush Out Hidden HIV Reservoirs
New Hope for HIV Eradication
Personalized Therapeutic Vaccine Shows Promise
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

October 15, 2008

Third Dose of Hep A Vaccine May Increase Immunity

An additional third booster shot of the hepatitis A virus (HAV) vaccine increased the chance of an HIV-positive person acquiring immunity to HAV and increased the number of antibodies against HAV after one year, according to the authors of a study published online in the Journal of Acquired Immune Deficiency Syndromes.

HIV treatment guidelines recommend that all people with HIV be vaccinated against HAV. Several studies, however, have found that people with HIV are less likely to develop antibodies to HAV following the traditional vaccination schedule, which is two doses given six months apart. Additional studies have also found that people with HIV who do develop HAV antibodies lose them more quickly than their HIV-negative counterparts.

To determine whether an additional “booster” shot of vaccine might improve responses, Odile Launay, MD, PhD, from the Université Paris Descartes in France, and her colleagues enrolled 99 HIV-positive patients between the ages of 19 and 55 who had never been vaccinated for HAV. Forty-nine of them got three doses of the vaccine at weeks 0, 4 and 24. The 50 other patients followed the standard vaccine schedule, with a shot at week 0 and the other at week 24.

Launay’s team found that about one year after the last vaccine dose in both groups, 86 percent of the patients in the three dose group and 70 percent of the patients in the two dose group had enough antibodies to HAV to provide protection. People in the three dose group also had many more antibodies remaining one year after the last dose than people in the two dose group. Though the difference in response rates appears large, it was not enough—given the small number of patients in the study—to reach statistical significance. This means that the difference in response could have occurred by chance. In general, people with lower CD4 counts and people who smoke were less likely in the study to develop HAV antibodies.

Though the additional vaccine dose did not reach statistical superiority to a standard vaccine schedule, the authors state that the evidence does tend to support an additional booster shot, particularly for vaccine non-responders, smokers and those with lower CD4 counts.

Search: hepatitis A virus, HAV, hep A, vaccine, vaccination, Odile Launay, Universite Paris Descartes


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy